Skip to main content

Table 1 Demographics and clinical features of the patient cohort

From: Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Demographics

AD

DLB

OND

PD

PDD

p Value

N

48

40

46

54

20

 

Sex, male, n (%)

23 (47.9)

27 (67.5)

18 (39.1)

35 (64.8)

13 (65.0)

0.026

Age, years

70.9 (9.6)

73.1 (6.3)

58.6 (17.3)

66.0 (8.9)

73.7 (5.7)

<0.001

MMSE score

18.4 (5.2)

19.2 (5.5)

26.7 (4.3)

27.8 (2.2)

19.2 (4.4)

<0.001

MoCA score

25.5 (3.3)

UPDRS-III score

27.9 (12.5)

24.3 (12.9)

33.3 (15.9)

0.092

H&Y score

3.0 (0.7)

1.7 (0.5)

3.6 (1.1)

<0.001

Center

Perugia

20 Kassel, 20 Antwerp

Perugia

Perugia

19 Kassel, 1 Perugia

 
  1. Abbreviations: AD Alzheimer’s disease, DLB Dementia with Lewy bodies, H&Y Hoehn & Yahr, MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, UPDRS-III Unified Parkinson’s Disease Rating Scale part III
  2. The number of patients included in each group, age, and sex, together with cognitive and motor scores, are reported. All data are reported using mean (SD), with the exception of the number of male patients, which is reported as a percentage. The p value is relative to the nonparametric analysis of variance test for the overall difference among the groups